How to Get Mounjaro in Hawaii

What Is Mounjaro and Why Hawaii Patients Are Requesting It

Mounjaro is a once-weekly injectable drug that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors simultaneously. That dual mechanism produces glucose lowering and body-weight reduction that exceeds what single-receptor GLP-1 agonists achieve at equivalent time points.

The FDA approved tirzepatide under the brand name Mounjaro for type 2 diabetes in May 2022. Eli Lilly's FDA approval label specifies use as an adjunct to diet and exercise in adults with type 2 diabetes mellitus. A separate formulation, Zepbound, received FDA approval for chronic weight management in November 2023. [1]

In SURPASS-2 (N=1,879), tirzepatide 15 mg reduced HbA1c by a mean of 2.58 percentage points versus 0.97 percentage points for semaglutide 1 mg at 40 weeks (P<0.001). Body weight fell by 11.2 kg in the tirzepatide 15 mg group versus 5.3 kg for semaglutide 1 mg. [2] Those results have driven substantial patient interest across all U.S. states, including Hawaii.

Hawaii's population faces above-average rates of obesity-related metabolic disease. According to the CDC's Behavioral Risk Factor Surveillance System, approximately 24.7% of Hawaii adults reported obesity in the most recent survey cycle, and diagnosed diabetes prevalence in the state sits near 9.7%. [3] Those figures help explain why prescriptions for GLP-1 and GIP/GLP-1 class drugs have grown rapidly across the islands.

Who Can Prescribe Mounjaro in Hawaii

Any Hawaii-licensed prescriber with independent or supervised prescribing authority may write a Mounjaro prescription. That group includes physicians (MD and DO), nurse practitioners (APRN with prescriptive authority), and physician assistants (PA). Hawaii grants APRNs full practice authority under Hawaii Revised Statutes §457-8.6, meaning a nurse practitioner does not require physician co-signature to prescribe Mounjaro. [4]

PAs in Hawaii prescribe under a supervising physician arrangement, though that arrangement does not require the physician to co-sign every prescription. A PA may independently transmit a Mounjaro prescription to a pharmacy after the supervising physician has approved a general prescribing protocol.

Telehealth providers licensed in Hawaii follow the same prescribing rules. The Hawaii Board of Medical Examiners and the Hawaii Board of Nursing both require that the prescriber hold an active Hawaii license before prescribing to a Hawaii-resident patient. A provider licensed only in California, for example, cannot legally prescribe to a Hawaii patient unless they also hold a Hawaii license or qualify under a recognized reciprocity or interstate compact arrangement. [5]

Hawaii Telehealth Rules for Mounjaro Prescriptions

Hawaii permits telehealth prescribing of non-controlled substances without a mandatory in-person visit. Mounjaro (tirzepatide) is not a controlled substance under the DEA scheduling system, so a provider may conduct an entirely audio-video telehealth encounter and issue a valid prescription. [6]

The Hawaii Telehealth Act (HRS §453-1.3) requires that the standard of care delivered via telehealth be equivalent to in-person care. That means a telehealth provider prescribing Mounjaro must still take a complete history, review relevant labs, document contraindications, and establish a legitimate clinical relationship before issuing the prescription. [7]

Several national telehealth platforms hold Hawaii licenses and actively prescribe tirzepatide to Hawaii residents. A patient initiates care by completing an online intake form, uploading recent labs, and attending a video visit with the prescribing clinician. Most platforms schedule that first visit within 48 to 72 hours of intake. After the visit, the prescription is transmitted electronically to either a local Hawaii pharmacy or a mail-order pharmacy licensed to dispense in Hawaii.

According to the American Telemedicine Association's policy framework, telehealth encounters for metabolic medications should document BMI, comorbidities, prior treatment history, and patient-reported contraindications at minimum. [8] HealthRX telehealth providers follow that documentation standard for every tirzepatide intake visit.

Labs and Clinical Criteria Required Before Prescribing

Before a provider in Hawaii writes a Mounjaro prescription, several baseline assessments are standard practice. Labs are not legally required to dispense the drug, but any provider adhering to the American Diabetes Association (ADA) Standards of Care will obtain them before initiating therapy. [9]

Recommended baseline labs include:

• Fasting plasma glucose or HbA1c (confirms diagnosis or screens for prediabetes)
• Comprehensive metabolic panel (creatinine, eGFR, liver enzymes)
• Fasting lipid panel
• TSH (tirzepatide carries a boxed warning regarding thyroid C-cell tumors; a baseline TSH contextualizes thyroid status)
• Urine albumin-to-creatinine ratio if T2D is the indication

The FDA-approved prescribing information for tirzepatide lists the following absolute contraindications: personal or family history of medullary thyroid carcinoma (MTC), and Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). [1] Providers should document that the patient does not carry those histories before the first dose.

For weight management indications, the ADA recommends considering anti-obesity pharmacotherapy in adults with BMI of 30 kg/m² or greater, or BMI of 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea. [9] Most commercial insurers in Hawaii apply similar BMI thresholds for prior authorization. Pancreatitis history, severe gastroparesis, and active pregnancy are clinical contraindications that require documentation.

The SURMOUNT-1 trial (N=2,539) reinforced those eligibility principles by enrolling adults with BMI <27 kg/m² only as an exception, confirming that the drug's benefit-risk profile is best established at higher BMI thresholds. In SURMOUNT-1, tirzepatide 15 mg produced 22.5% mean weight reduction at 72 weeks versus 2.4% for placebo (P<0.001). [10]

How to Fill a Mounjaro Prescription at a Hawaii Pharmacy

Once a valid prescription exists, patients have three primary dispensing options in Hawaii.

Retail chain pharmacies. Major chains operating in Hawaii, including CVS, Walgreens, and Longs Drugs (a CVS subsidiary with strong Hawaii presence), stock branded Mounjaro at select locations. Stock availability varies by island and by dose. The 2.5 mg and 5 mg starter doses tend to be more consistently available than the 10 mg and 15 mg maintenance doses. Patients should call ahead to confirm inventory because tirzepatide supply has been intermittent nationally since 2023. [11]

Mail-order pharmacies licensed in Hawaii. A pharmacy holding a Hawaii Pharmacy Non-Resident License may ship a 30-day or 90-day supply of Mounjaro to a Hawaii address. Processing time from prescription receipt to delivery at a Hawaii address typically runs 5 to 10 business days depending on the carrier and which island receives the shipment. Outer island patients on Maui, Kauai, the Big Island, and Molokai should add 1 to 2 business days for inter-island freight.

503A compounding pharmacies. Hawaii law permits licensed 503A compounding pharmacies to prepare tirzepatide compounds for individual patients when a valid prescription specifies a customized formulation. The FDA removed tirzepatide from the shortage list for the branded 2.5 mg and 5 mg doses in December 2024, which limits but does not eliminate the ability of 503A pharmacies to compound it. Compounded tirzepatide is not FDA-approved and does not carry the same manufacturing oversight as the branded Mounjaro pen. Patients should verify that any 503A pharmacy they use holds an active Hawaii Board of Pharmacy registration or a non-resident pharmacy license issued by Hawaii. [12]

Insurance Coverage and Prior Authorization in Hawaii

Hawaii commercial insurance coverage for Mounjaro varies significantly by plan. For the type 2 diabetes indication, many plans cover tirzepatide after step therapy with metformin and at least one other oral agent. For weight management, coverage is considerably more restrictive.

Hawaii Medicaid (Med-QUEST) does not currently cover Mounjaro for weight loss. Coverage for the T2D indication under Med-QUEST is limited and requires prior authorization with documented HbA1c above a plan-specific threshold, typically 7.5% or higher. Patients should call their Med-QUEST plan directly to obtain current formulary status because coverage decisions update annually. [13]

For commercial plans, prior authorization documentation typically requires:

1. Confirmed diagnosis (T2D with HbA1c, or obesity with BMI documentation)
2. Evidence of lifestyle intervention for at least 3 months
3. Step therapy failure documentation (metformin for T2D; orlistat or phentermine/topiramate for weight management)
4. Absence of listed contraindications
5. Prescriber attestation of medical necessity

The American Association of Clinical Endocrinology (AACE) 2023 Obesity Clinical Practice Guidelines state that "anti-obesity medications should be offered to patients with obesity or overweight with complications when lifestyle therapy alone is insufficient." [14] That language supports medical necessity arguments in prior authorization appeals.

List price for branded Mounjaro runs approximately $1,069 per month for a 4-pen box (four weekly doses). Eli Lilly's Mounjaro Savings Card reduces out-of-pocket cost to as low as $25 per month for eligible commercially insured patients. Uninsured patients pay the full list price unless they qualify for Lilly's patient assistance program, which has income-based eligibility thresholds. [15]

Step-by-Step: Getting Mounjaro Through a Hawaii Telehealth Provider

The process below applies to patients using a telehealth platform licensed in Hawaii. It assumes the patient does not yet have a Mounjaro prescription.

Step 1: Complete the online intake (Day 1). Most platforms request height, weight, current medications, medical history, and a photo ID confirming Hawaii residency. Upload any labs from the prior 6 months if available.

Step 2: Schedule and attend the video visit (Days 1 to 3). The prescribing clinician reviews your intake, asks clarifying questions, orders labs if needed, and discusses the dosing schedule. The initial dose is always 2.5 mg once weekly for 4 weeks.

Step 3: Lab draw if needed (Days 3 to 7). If labs are ordered, you visit a LabCorp or Quest Diagnostics location. Both operate draw sites across Oahu, Maui, and the Big Island. Quest Diagnostics has a patient service center in Hilo and Kailua-Kona; LabCorp has sites in Honolulu and Kailua. Results typically return within 1 to 3 business days.

Step 4: Prescription transmission (Days 3 to 5). Once labs are reviewed and approved, the provider transmits the prescription to your chosen pharmacy. For mail-order, the prescription goes electronically same-day.

Step 5: Shipment and delivery (Days 5 to 14). Retail Hawaii pharmacies fill prescriptions within 24 hours of receipt when stock is available. Mail-order delivery to Oahu averages 5 to 7 business days; outer islands add 2 days.

Step 6: Injection training. Mounjaro comes in a single-dose autoinjector pen. Inject subcutaneously into the abdomen, thigh, or upper arm once weekly, rotating sites. The FDA prescribing information specifies that the injection day may be changed as long as the last dose was at least 3 days prior to the new injection day. [1]

Transferring an Existing Mounjaro Prescription to Hawaii

Patients relocating to Hawaii from another state, or snowbirds spending extended time in the islands, often ask whether they can transfer their existing Mounjaro prescription. The answer depends on where the prescription currently resides.

If the prescription is at a national chain pharmacy (CVS, Walgreens, Walmart), transfer to a Hawaii branch of the same chain is straightforward. Call the destination pharmacy with your name, date of birth, and origin pharmacy details. Non-controlled substance prescriptions transfer between licensed pharmacies in different states without restriction under most states' pharmacy laws.

If the prescription was written by an out-of-state provider who is not licensed in Hawaii, the prescription remains valid for filling until refills are exhausted or the prescription expires (typically one year from the date written). Hawaii pharmacies may fill an out-of-state prescription for a non-controlled substance as long as the prescribing provider held a valid license in their home state at the time of writing. [16]

Once refills run out, a Hawaii-licensed provider must issue a new prescription. That is when establishing care with a Hawaii telehealth provider or local endocrinologist becomes necessary. Patients should plan ahead and initiate a new provider relationship before their current supply runs out, particularly given the 48 to 72-hour telehealth scheduling window.

Dosing Schedule and Titration in Hawaii Practice

Mounjaro titration follows a fixed schedule regardless of where in the country the patient lives. The FDA-approved starting dose is 2.5 mg once weekly for 4 weeks, increasing to 5 mg for another 4 weeks. Providers may then titrate in 2.5 mg increments at 4-week intervals based on tolerability. The maximum approved dose is 15 mg once weekly. [1]

SURPASS-2 data show that the 10 mg and 15 mg doses drive the largest glycemic and weight benefits. At 40 weeks, the 15 mg dose reduced body weight by 11.2 kg and HbA1c by 2.58 percentage points, compared with 7.6 kg and 2.01 percentage points for the 5 mg dose. [2] Most providers in Hawaii who prescribe for weight management aim to reach at least 10 mg if tolerated.

Common tolerability issues at titration include nausea (reported in 17.3% of patients on 15 mg in SURPASS-2), diarrhea (13.2%), vomiting (9.4%), and constipation (11.8%). [2] Hawaii providers generally manage these by slowing titration rather than discontinuing therapy. Injecting at bedtime and eating smaller, lower-fat meals around the injection day both reduce GI side effects in clinical experience.

The Endocrine Society's 2023 clinical practice guideline on pharmacotherapy for obesity recommends continued monitoring every 3 months during dose escalation, including weight, blood pressure, heart rate, and metabolic labs. [17] Hawaii telehealth providers conducting quarterly check-ins fulfill that monitoring standard via video visit.

What Happens If Prior Authorization Is Denied in Hawaii

Insurance denial is common on the first submission, particularly for weight management. Patients have a right to appeal under Hawaii's insurance laws. The Hawaii Insurance Division oversees insurer conduct under Hawaii Revised Statutes Chapter 432. [18]

A strong appeal letter should include the prescriber's clinical notes documenting the diagnosis, comorbidities, BMI, lifestyle intervention history, and step therapy failures. Attaching peer-reviewed evidence, such as the SURPASS-2 or SURMOUNT-1 trial data, strengthens the medical necessity argument. The Obesity Medicine Association's position statement supporting pharmacotherapy for obesity management may also be cited in appeals. [19]

If the internal appeal fails, Hawaii patients may request an Independent Medical Review (IMR) through the Hawaii Insurance Division within 60 days of the final denial. The IMR process is free to the patient, and the reviewer's decision is binding on the insurer for clinical necessity determinations. [18]

Patients who cannot obtain insurance coverage and cannot afford the list price should discuss compounded tirzepatide options with their provider, keeping in mind the quality and regulatory differences outlined in the 503A pharmacy section above.